Angelika Eggert

This study develops a method to detect minimal residual disease in neuroblastoma using ecDNA breakpoints, achieving high sensitivity and specificity in bone marrow samples.

The paper introduces circVDJ-seq for efficient T cell receptor profiling from single-cell and spatial multi-omics data, revealing distinct immune microenvironments and T cell clonality patterns in various clinical contexts.

This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

This paper develops CancerPAM, a bioinformatics pipeline for identifying CRISPR knock-in sites to remodel the tumor microenvironment, enhancing CAR T cell therapy in solid tumors.

This paper shows that high MYCN levels in neuroblastoma reduce L1CAM expression, limiting CAR T cell efficacy, and that inhibiting MYCN with MLN8237 restores L1CAM and enhances CAR T cell activity.

The paper identifies gene dosage effects on telomere maintenance and disease pathways in neuroblastoma using genomic and transcriptomic data from 115 tumors.